Concepta signs marketing contract in China

RNS Number : 9380E
Concepta PLC
15 February 2018
 

15 February 2018

Concepta plc

("Concepta" or the "Company")

Concepta signs contract in China to support marketing of myLotus in Chinese hospitals

 

Concepta plc (AIM: CPT), the UK healthcare company and developer of a proprietary product targeted at the mobile health market with a primary focus on women's fertility, is pleased to announce that it has signed a marketing agreement with Wei Yi Bei Lian (Shanghai) Information Technology Co., Ltd ("BB Link").

BB Link offers free WiFi to waiting rooms in 1,500 maternity hospitals across China. Concepta has developed a landing page that will be displayed when patients connect to this WiFi service. The page will give an overview of the myLotus product and a link to the Concepta website where more in depth information can be found. Initially, Concepta's landing page will be launched in a select number of hospitals, and longer term, the Company will be able to reach hundreds of thousands of women in a phased rollout, through a highly targeted marketing channel.

Concepta's distributors will also train the doctors at these hospitals on the myLotus product, enabling them to provide further detailed information and recommendations to patients that could benefit from its use.

Erik Henau, CEO says: "Co-operation with BB Link allows us to target the most relevant potential users of myLotus in a cost-effective way. Additionally, if women are able to read about the product prior to seeing the doctor, there is a greater scope for market penetration.

"BB Link has developed a sophisticated platform with metrics that permit the measurement of campaign success. We will start with a trial that will help us to refine our key messages to our consumers and to learn how the information links to the logistics of the hospital route.

"This is an important step in building our consumer brand in China and in working with the hospital route to market."

Enquiries:

The Company

Erik Henau

CEO

Tel: +44 (0) 1234 866601

 

SPARK Advisory Partners Limited (Nomad)

Neil Baldwin / Mark Brady

Tel: +44 (0)20 368 355

 

NOVUM Securities Limited (Broker)

Colin Rowbury

+44 (0) 20 7399 9400

 

Yellow Jersey (Financial PR)

Georgia Colkin / Joe Burgess / Katie Bairsto

Tel: +44 (0) 776 932 5254

 

About Concepta Plc:

Concepta plc is an AIM-quoted pioneering UK healthcare company that has developed a proprietary product, myLotus, targeted at the personalised mobile health market with a primary focus on unexplained infertility* in women.

myLotus is currently the only consumer product which allows both quantitative and qualitative measurements of a woman's personal LH**and hCG***hormone levels in a home test, facilitating higher conception rates and early diagnosis of issues with fertility hormones. The proposition of myLotus is to help women conceive naturally.

Concepta has made significant progress recently, establishing agreements with a number of distributors in China where myLotus has been given cFDA approval. Concepta is initially targeting the traditional route to market in China through Chinese hospitals and plans to add the direct-to-consumer route in the near future.

The Company is also well on its way to achieving CE-marking and commencing its direct-to-consumer launch in the UK and Europe in H1 2018. The Company has identified a significant global market opportunity, with revenue potential of the Chinese and EU unexplained infertility market estimated to be worth c.£600m per annum.

*Unexplained infertility refers to women that have been unable to conceive after 6 months of trying. This highly motivated target group of consumers won't typically be offered medical intervention until 12 months of unsuccessfully trying, with IVF not offered until two years. Research indicates couples start to take positive action ahead of this time and there is little medical support to help them do so.

** LH: Luteinising hormone is produced by the pituitary gland and is one of the main hormones that control the reproductive system.

*** hCG: Human chorionic gonadotropin is a hormone produced by the placenta after implantation and is an indicator of pregnancy.

 

About RNS Reach announcements

RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRALFFFFFEISLIT
UK 100

Latest directors dealings